| ASMs | antiseizure medications |
| BCVA | best-corrected visual acuity |
| CBZ | carbamazepine |
| CLB | clobazam |
| CLZ | clonazepam |
| CSF | cerebrospinal fluid |
| EEG | electroencephalography |
| EMG | electromyography |
| ETDRS | early treatment diabetic retinopathy study |
| FDG | fluorodeoxyglucose |
| GCL | ganglion cell layer |
| IQ | intelligence quotient |
| JL-Back AVG | jerk-locked back averaging analysis |
| LEV | levetiracetam |
| LLR | long loop reflex |
| MERFF | myoclonic epilepsy with ragged red fibers |
| MELAS | mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes |
| MEP | motor-evoked potential |
| MRI | magnetic resonance imaging |
| NAA | N-acetyl-aspartate |
| NGS | next generation sequencing |
| OCT | optical coherence tomography |
| PB | phenobarbital |
| PER | perampanel |
| PET | positron emission tomography |
| PIR | piracetam |
| PME | progressive myoclonus epilepsies |
| SEP | somatosensory evoked potentials |
| TCS | tonic–clonic seizures |
| TPM | topiramate |
| UMRS | unified myoclonus rating scale |
| VEP | visual evoked potential |
| VPA | valproate |
| ZNS | zonisamide |